2020
The Surgical Resection of Brainstem Glioma: Outcomes and Prognostic Factors
Faulkner H, Arnaout O, Hoshide R, Young IM, Yeung JT, Sughrue ME, Teo C. The Surgical Resection of Brainstem Glioma: Outcomes and Prognostic Factors. World Neurosurgery 2020, 146: e639-e650. PMID: 33152495, DOI: 10.1016/j.wneu.2020.10.147.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAstrocytomaAtaxiaBrain Stem NeoplasmsCerebrospinal Fluid LeakChildChild, PreschoolDiplopiaEpendymomaFemaleGlioblastomaGliomaHeadacheHumansHydrocephalusInfantInfant, NewbornKaplan-Meier EstimateKarnofsky Performance StatusMachine LearningMagnetic Resonance ImagingMaleMiddle AgedMultivariate AnalysisNauseaNeoplasm GradingNeoplasm, ResidualNeurosurgical ProceduresPostoperative ComplicationsPrognosisRetrospective StudiesSurvival RateTumor BurdenVomitingYoung AdultConceptsBrainstem gliomasSurgical resectionPrognostic factorsSurgical treatmentTransient neurologic deficitsRadical surgical resectionHigh-grade tumorsPostoperative radiographic evaluationMagnetic resonance imagingChart reviewNeurologic deficitsOverall survivalSurgical candidatesConfers survival advantageMedian ageSurgical indicationsPatient selectionSurvival outcomesRadiographic evaluationSelect subgroupRadiographic featuresPrimary treatmentPermanent deficitsSurvival advantageTreatment selection
2013
LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma
Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H. LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. Clinical Cancer Research 2013, 19: 1816-1826. PMID: 23401227, PMCID: PMC3618546, DOI: 10.1158/1078-0432.ccr-12-2861.Peer-Reviewed Original ResearchConceptsHLA class IT cell infiltrationHLA class IILoss of heterozygosityHLA class IIIClass IOverall survivalAdult glioblastomaClass IIIHLA class I expressionHuman leukocyte antigen (HLA) class IClass IIEfficacy of immunotherapyShorter overall survivalCytotoxic T cellsClass I expressionAntigen class ICross-sectional analysisAdult patientsShorter survivalImmunohistochemical evaluationT cellsHLA class I regionI expressionDownregulated expression